Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 98 Solid NorditropinⓇ sales growth Norditropin® reported sales DKK billion • 2.5 CAGR¹ 9.5% 2.0 1.5 1.0 0.5 0.0 Q3 2011 1 CAGR for 5-year period changing diabetes Q3 2016 • Key Norditropin® properties Product characteristics: Premixed, prefilled multi-use delivery systems available in multiple strengths, and stable at room temperature Expanded indications: GHD, GHDA, Noonan Syndrome, Turner Syndrome, SGA indication, Idiopathic short stature • Easy to use FlexPro® device Medical and Clinical support programmes Patient support programmes novo nordisk

View entire presentation